The DOI matches its Crossref record; 1,861 of the 1,959 references it cites were found in a registry or an index; 7 of the 11 sources its claims cite were checked for support.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Open accessAbstract
Objective The objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other health care professionals and stakeholders, and individuals with diabetes and their caregivers. Methods The American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022. Selected studies from results of literature searches composed the evidence base to update 2015 recommendations as well as to develop new recommendations based on review of clinical evidence, current practice, expertise, and consensus, according to established American Association of Clinical Endocrinology protocol for guideline development. Results This guideline includes 170 updated and new evidence-based clinical practice recommendations for the comprehensive care of persons with diabetes. Recommendations are divided into four sections: (1) screening, diagnosis, glycemic targets, and glycemic monitoring; (2) comorbidities and complications, including obesity and management with lifestyle, nutrition, and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic kidney disease, and cardiovascular disease; (3) management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy; (4) education and new topics regarding diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations on cancer risk, nonpharmacologic components of pediatric care plans, depression, education and team approach, occupational risk, role of sleep medicine, and vaccinations in persons with diabetes. Conclusions This updated clinical practice guideline provides evidence-based recommendations to assist with person-centered, team-based clinical decision-making to improve the care of persons with diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 of 11 cited sources checked · 0 supported · 0 flagged · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A glucose level ≥200 mg/dL in the presence of hyperglycemia symptoms such as polyuria and polydipsia confirm the diagnosis of DM.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Could not verifycites [6] sourceExperimental — accuracy not yet measured
The Diagnostic testing passage (page unavailable) discusses fasting glucose, HbA1c, C-peptide, and antibody tests for evaluating MODY. Neither it nor the other retrieved passages gives a ≥200 mg/dL glucose threshold with hyperglycemia symptoms for diagnosing diabetes; searches for that threshold and symptom-based criterion found no supporting passage in our copy. (LLM, conf=0.73)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The concordance between FPG, 2-hour PG, and A1C is not perfect; thus, the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Partly supportedcites [3] sourceExperimental — accuracy not yet measured
The paper’s introductory passage says diabetes diagnosis requires confirmation of an elevated glucose or HbA1c result and that two different tests above diagnostic thresholds can provide confirmation. It also says repeating the same test on a later sample is preferred, so two different tests are not required. The Discussion says guidelines were unclear about using two tests from one sample; our copy does not address the quoted exception for symptoms with glucose of at least 200 mg/dL or concordance involving 2-hour PG. (LLM, conf=0.87)
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The paper’s opening section says that FPG or 2-hour glucose meets the usual diagnostic criteria when abnormal on more than one occasion, and that classic symptoms with a single random plasma glucose of at least 200 mg/dL are diagnostic. It does not say that confirmation requires two different tests (FPG and A1C), or that two abnormal results from the same sample suffice. Its discussion of test variability supports imperfect reproducibility, but not that specific confirmation rule. (LLM, conf=0.88)
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Discussion reports imperfect agreement among HbA1c, fasting plasma glucose, and 2-hour plasma glucose, and says diabetes diagnosis requires repeated measurement rather than a single test. It does not specify that the two abnormal results must be from different tests, describe the same-sample or different-day options, or state an exception for hyperglycemic symptoms with glucose of at least 200 mg/dL. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Universal screening is recommended, as selective screening (only in women with risk factors) would miss a significant number of women with GDM and universal screening has been shown to be cost-effective compared with selective screening.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [50] sourceExperimental — accuracy not yet measured
The Conclusions recommend GDM screening at 24–28 weeks using a 75-g OGTT. The paper does not compare universal screening with risk-factor-based selective screening or report that universal screening is cost-effective; searches for selective screening and cost-effectiveness found no such comparison. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [51] source
- Not checked — no full text of the sourcecites [52] source
- Not checked — no full text of the sourcecites [53] source
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
Section 5.2 recommends universal testing because risk-factor-based selective testing has poor sensitivity for detecting GDM. But section 5.4 says there is a lack of good evidence for the cost-effectiveness of universal testing in both high- and low-resource countries; it does not establish that universal screening is cost-effective compared with selective screening. (LLM, conf=0.90)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Conclusions discuss childhood glucose outcomes after maternal GDM, not whether universal screening is recommended. Searches of our copy for selective screening, missed cases, and cost-effectiveness found no passage addressing those claims. (LLM, conf=0.76)
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Real-time CGM (rtCGM) or isCGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“DM is diagnosed by using any of 3 established criteria for elevated blood glucose (BG) concentrations (Table 4). FPG ≥126 mg/dL, 2-hour PG ≥ 200 mg/dL during 75-g OGTT, and A1C ≥ 6.5% are equally appropriate for diagnostic screening (Table 4).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For most hospitalized persons with hyperglycemia in both the intensive care unit (ICU) and non-ICU settings, a glucose range of 140 to 180 mg/dL is recommended, provided this target can be safely achieved (Table 6).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 2. What are the glycemic treatment goals for persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Diabetic peripheral neuropathy (DPN) is a clinical diagnosis. A comprehensive differential diagnosis should be considered to rule out nondiabetic neuropathies.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All persons who use insulin should use CGM or perform BG monitoring (BGM) a minimum of twice daily and ideally before any insulin injection.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A1C should be measured at least semiannually in all persons with DM and at least quarterly in persons not at their glycemic target.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Screening for DPN should be done at diagnosis of T2D, within 5 years of the diagnosis of T1D, and subsequently annually or whenever symptoms occur, by performing a clinical history and physical exam.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Continuous access to CGM for daily use is suggested for people living with T2DM at higher risk of hypoglycaemia, similar to the current CGM clinical practice guideline recommendations from Diabetes Canada 56 and the American Association of Clinical Endocrinologists. 57”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredIn the citing paper
“Approximately 2–5 times more patients discontinued orforglipron versus placebo due to adverse events, comparable to other GLP‐1 receptor agonists where 5%–15% discontinue in clinical trials [48].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [48]
In the citing paper
“Current guideline recommendations by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American College of Sports Medicine (ACSM), American Association of Clinical Endocrinology (AACE), and the American Heart Association (AHA) advocate regular resistance and aerobic exercise, as well as physical activity such as increasing daily steps to avoid sed”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
In the citing paper
“AACE and the ADA recommend avoiding no more than 2 to 3 days between exercise routines to maintain improvement in insulin sensitivity.”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
CKD recommendation and rationale give different SGLT2i eligibility thresholds
MajorRecommendation 6.4 covers people with T2D and CKD whose eGFR is at least 20, but its evidence base sets the general threshold above 25. The lower threshold is described there only for empagliflozin in people with heart failure, leaving those without heart failure between 20 and 25 covered by the recommendation but not the stated general rule.
“An SGLT2i with proven benefit is recommended as foundational therapy for persons with T2D and CKD with eGFR ≥20 mL/min/1.73 m2 to reduce progression of CKD and risk of CVD.”
“An SGLT2i with proven kidney protection is recommended for people with T2D who have an eGFR >25 mL/min/1.73 m2 irrespective of albuminuria to reduce risks of DKD or CKD in DM and CVD.425,443–469 In those with HF, one agent in the class, empagliflozin, can be used with an eGFR as low as 20 mL/min/1.73 m2.”
GDM fasting threshold differs at 92 mg/dL
MinorThe one-step diagnostic recommendation includes a fasting glucose of exactly 92 mg/dL, while the later diagnostic criteria require a value greater than 92 mg/dL. The two rules classify a patient at that boundary differently.
“The one-step approach uses a 2-hour 75-g oral glucose tolerance test (OGTT) after ≥8 hours of fasting with diagnostic cutoffs of one or more FPG ≥92 mg/dL, 1-hour PG ≥180 mg/dL, or 2-hour PG ≥153 mg/dL.”
“Glucose criteria diagnostic for GDM are an FPG >92 mg/dL, 1-hour postglucose challenge value ≥180 mg/dL, or 2-hour value ≥153 mg/dL.”
Semaglutide weekly dose changes by a factor of 1,000
MinorThe same discussion gives the higher weekly semaglutide dose as 2.4 mg and then describes an equivalent weekly dose as 2.4 g. Those quantities differ by a factor of 1,000.
“A phase 2 study in persons with biopsy-proven NASH using a daily injection equivalent to semaglutide 2.4 g/week demonstrated 13% weight loss”
“Subcutaneous semaglutide at the higher dose of 2.4 mg/week has been approved for chronic weight management”
Diabetes confirmation alternates between two results and two different tests
MinorRecommendation 1.1 permits two abnormal results on different days without requiring different tests. Its evidence base instead says confirmation requires two different tests, specifically fasting glucose and A1C, so the rules disagree on whether repeating one test suffices.
“Diagnosis of DM requires 2 abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
“the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Cites a retracted work: 10.1016/j.diabres.2021.108972
MajorThe cited work was retracted on 2021-07-31 (notice 10.1016/j.diabres.2021.108972), before this paper was published (2022-10). Its authors could have known.
Cited work 10.1016/j.diabres.2021.108972 · retracted 2021-07-31 · notice 10.1016/j.diabres.2021.108972 · this paper published 2022-10
“Adler, 2021, Reprint of: Classification of diabetes mellitus, Diabetes Res Clin Pract, 10.1016/j.diabres.2021.108972”
Citations
Cites
1 retracted
Items 601–800 of 1,862
Lee, C. D., Folsom, A. R., Pankow, J. S., & Brancati, F. L. (2004) · Circulation · doi:10.1161/01.cir.0000116389.61864.de · Cited by 276
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Musuuza, J., Sutherland, B. L., Kurter, S., Balasubramanian, P., Bartels, C. M., & Brennan, M. B. (2020) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.08.244 · Cited by 274
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M. A., & Rosebraugh, C. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 273
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Schwingshackl, L., Chaimani, A., Hoffmann, G., Schwedhelm, C., & Boeing, H. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-017-0352-x · Cited by 273
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
Adult-onset autoimmune diabetes: current knowledge and implications for management
Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.99 · Cited by 271
A pragmatic, randomized clinical trial of gestational diabetes screening
Hillier, T. A., Pedula, K. L., Ogasawara, K. K., Vesco, K. K., Oshiro, C. E. S., Lubarsky, S. L., & Van Marter, J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026028 · Cited by 270
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
Sainsbury, E., Kizirian, N. V., Partridge, S. R., Gill, T., Colagiuri, S., & Gibson, A. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.026 · Cited by 268
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Banerji, M. A., Chaiken, R. L., Huey, H., Tuomi, T., Norin, A. J., Mackay, I. R., Rowley, M. J., Zimmet, P. Z., & Lebovitz, H. E. (1994) · Diabetes · doi:10.2337/diab.43.6.741 · Cited by 266
Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.-P., Kassai, B., Moreau, A., Gueyffier, F., & Cornu, C. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001204 · Cited by 266
Feinkohl, I., Aung, P. P., Keller, M., Robertson, C. M., Morling, J. R., McLachlan, S., Deary, I. J., Frier, B. M., Strachan, M. W. J., Price, J. F., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1384 · Cited by 266
Li, X., Liu, Y., Zheng, Y., Wang, P., & Zhang, Y. (2018) · Nutrients · doi:10.3390/nu10030375 · Cited by 266
Knight, S. R., & Morris, P. J. (2010) · Transplantation · doi:10.1097/tp.0b013e3181c518cc · Cited by 265
Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy
Mathiesen, E. R., Kinsley, B., Amiel, S. A., Heller, S., McCance, D., Duran, S., Bellaire, S., Raben, A., & on behalf of the Insulin Aspart Pregnancy Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1887 · Cited by 265
Aversa, A., Bruzziches, R., Francomano, D., Rosano, G., Isidori, A. M., Lenzi, A., & Spera, G. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01931.x · Cited by 265
Jensen, T. S., Karlsson, P., Gylfadottir, S. S., Andersen, S. T., Bennett, D. L., Tankisi, H., Finnerup, N. B., Terkelsen, A. J., Khan, K., Themistocleous, A. C., et al. (2021) · Brain · doi:10.1093/brain/awab079 · Cited by 265
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Chalmers, J., & Cooper, M. E. (2008) · New England Journal of Medicine · doi:10.1056/nejme0807625 · Cited by 263
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13301 · Cited by 263
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Self-citationCharleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Cavero-Redondo, I., Peleteiro, B., Álvarez-Bueno, C., Rodriguez-Artalejo, F., & Martínez-Vizcaíno, V. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-015949 · Cited by 260
Schwartz, S. L., Etropolski, M. S., Shapiro, D. Y., Okamoto, A., Lange, R., Häeussler, J., & Rauschkolb, C. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.537589 · Cited by 259
Strasser, B., Siebert, U., & Schobersberger, W. (2010) · Sports Medicine · doi:10.2165/11531380-000000000-00000 · Cited by 258
Body mass index and risk of prostate cancer in U.S. health professionals
Giovannucci, E., Rimm, E. B., Liu, Y., Leitzmann, M., Wu, K., Stampfer, M. J., & Willett, W. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg009 · Cited by 258
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Desai, M., Li, Q., Deng, H., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035901 · Cited by 257
Liese, A. D., Nichols, M., Sun, X., D'Agostino, R. B., & Haffner, S. M. (2009) · Diabetes Care · doi:10.2337/dc09-0228 · Cited by 256
Davis, N. J., Tomuta, N., Schechter, C., Isasi, C. R., Segal-Isaacson, C. J., Stein, D., Zonszein, J., & Wylie-Rosett, J. (2009) · Diabetes Care · doi:10.2337/dc08-2108 · Cited by 256
Gregory, J. M., Slaughter, J. C., Duffus, S. H., Smith, T. J., LeStourgeon, L. M., Jaser, S. S., McCoy, A. B., Luther, J. M., Giovannetti, E. R., BOEDER, S. C., et al. (2020) · Diabetes Care · doi:10.2337/dc20-2260 · Cited by 256
Block, G., Azar, K. M., Romanelli, R. J., Block, T. J., Hopkins, D., Carpenter, H. A., Dolginsky, M. S., Hudes, M. L., Palaniappan, L. P., & Block, C. H. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4897 · Cited by 255
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
Tso, L. O., Costello, M., Albuquerque, L. E. T., Andriolo, R. B., & Macedo, C. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006105.pub3 · Cited by 255
Intensive Insulin Therapy in Hospitalized Patients: A Systematic Review
Kansagara, D. L., Fu, R. F., Freeman, M., Wolf, F., & Helfand, M. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-4-201102150-00008 · Cited by 252
Screening for coronary artery disease in patients with diabetes
Bax, J. J., Young, L. H., Frye, R. L., Bonow, R. O., Steinberg, H. O., & Barrett, E. J. (2007) · Diabetes Care · doi:10.2337/dc07-9927 · Cited by 251
Dietary protein intake and risk of type 2 diabetes in US men and women
Malik, V. S., Li, Y., Tobias, D. K., Pan, A., & Hu, F. B. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv268 · Cited by 251
Raskin, P., Klaff, L., Bergenstal, R., Hallé, J. P., Donley, D., & Mecca, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1666 · Cited by 250
He, X., Li, J., Wang, B., Yao, Q., Li, L., Song, R., Shi, X., & Zhang, J.-A. (2017) · Endocrine · doi:10.1007/s12020-016-1168-2 · Cited by 250
Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00555.x · Cited by 249
Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Andersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2062 · Cited by 248
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248
Self-citationCombination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Adiposity and risk of thyroid cancer: A systematic review and meta-analysis
Schmid, D., Ricci, C., Behrens, G., & Leitzmann, M. F. (2015) · Obesity Reviews · doi:10.1111/obr.12321 · Cited by 244
Timpel, P., Oswald, S., Schwarz, P. E. H., & Harst, L. (2020) · Journal of Medical Internet Research · doi:10.2196/16791 · Cited by 243
Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.044 · Cited by 243
Self-citationKosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00180-7 · Cited by 243
Self-citationŠoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0888 · Cited by 242
Diabetes: A metabolic and reproductive disorder in women
Thong, E. P., Codner, E., Laven, J. S. E., & Teede, H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30345-6 · Cited by 242
Painful sensory polyneuropathy associated with impaired glucose tolerance
Singleton, J. R., Smith, A. G., & Bromberg, M. B. (2001) · Muscle & Nerve · doi:10.1002/mus.1136 · Cited by 241
Saslow, L. R., Daubenmier, J. J., Moskowitz, J. T., Kim, S., Murphy, E. J., Phinney, S. D., Ploutz-Snyder, R., Goldman, V., Cox, R. M., Mason, A. E., et al. (2017) · Nutrition & Diabetes · doi:10.1038/s41387-017-0006-9 · Cited by 241
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240
Garber, A. J., Handelsman, Y., EINHORN, D. F., Bergman, D. A., Bloomgarden, Z. T., Fonseca, V. A., Garvey, W. T., Gavin, J. R., Grunberger, G., Horton, E. S., et al. (2008) · Endocrine Practice · doi:10.4158/ep.14.7.933 · Cited by 239
Self-citationWilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.004 · Cited by 239
Biologic and Quality-of-Life Outcomes From the Mediterranean Lifestyle Program
Toobert, D. J., Glasgow, R. E., Strycker, L. A., Barrera, M., Radcliffe, J. L., Wander, R. C., & Bagdade, J. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2288 · Cited by 238
Garvey, W. T., Garber, A. J., Mechanick, J. I., Bray, G. A., Dagogo-Jack, S., Einhorn, D., Grunberger, G., Handelsman, Y., Hennekens, C. H., Hurley, D. L., et al. (2014) · Endocrine Practice · doi:10.4158/ep14280.ps · Cited by 238
Self-citation(2014) · PubMed · Cited by 237
Pioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
Self-citationUmpierrez, G. E., Latif, K., Stoever, J., Cuervo, R., Park, L., X. Freire, A., & E. Kitabchi, A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.010 · Cited by 236
Self-citationZinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Reznik, Y., Cohen, O., Aronson, R., Conget, I., Runzis, S., Castaneda, J., & Lee, S. W. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61037-0 · Cited by 233
Selenium exposure and the risk of type 2 diabetes: A systematic review and meta-analysis
Vinceti, M., Filippini, T., & Rothman, K. J. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0422-8 · Cited by 233
Kuna, S. T., Reboussin, D. M., Borradaile, K. E., Sanders, M. H., Millman, R. P., Zammit, G., Newman, A. B., Wadden, T. A., Jakicic, J. M., Wing, R. R., et al. (2013) · Sleep · doi:10.5665/sleep.2618 · Cited by 231
Halden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T. (2019) · Diabetes Care · doi:10.2337/dc19-0093 · Cited by 231
Davidson, P. C., Steed, R. D., & Bode, B. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2418 · Cited by 230
The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy
Singleton, J. R., Bixby, B. A., Russell, J. W., Feldman, E. L., Peltier, A., Goldstein, J. M., Howard, J., & Smith, A. G. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00180.x · Cited by 229
Pivetta, B., Chen, L., Nagappa, M., Saripella, A., Waseem, R., Englesakis, M. F., & Chung, F. F. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.1009 · Cited by 229
Wahabi, H. A., Alzeidan, R. A., Bawazeer, G. A., Alansari, L. A., & Esmaeil, S. A. (2010) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-10-63 · Cited by 228
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M., & Kudva, Y. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000591 · Cited by 228
Insulin resistance and coronary heart disease in nondiabetic individuals
Reaven, G. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241885 · Cited by 227
Fracture risk following bariatric surgery: A population-based study
Nakamura, K. M., Haglind, E. G. C., Clowes, J. A., Achenbach, S. J., Atkinson, E. J., Melton, L. J., & Kennel, K. A. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2463-x · Cited by 227
Treatment of diabetic ketoacidosis with subcutaneous insulin aspart
Umpierrez, G. E., Cuervo, R., Karabell, A., Latif, K., Freire, A. X., & Kitabchi, A. E. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1873 · Cited by 227
Self-citationTonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2453 · Cited by 226
Bendsen, N. T., Christensen, R., Bartels, E. M., & Astrup, A. (2011) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2011.34 · Cited by 225
AACE/ACE comprehensive diabetes management algorithm 2015
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep15693.cs · Cited by 225
Self-citationRuedy, K. J., Parkin, C. G., Riddlesworth, T. D., & Graham, C. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817704445 · Cited by 225
Sniderman, A. D., St-Pierre, A. C., Cantin, B., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00262-5 · Cited by 224
Odgers‐Jewell, K., Ball, L. E., Kelly, J. T., Isenring, E. A., Reidlinger, D. P., & Thomas, R. (2017) · Diabetic Medicine · doi:10.1111/dme.13340 · Cited by 224
Vega-López, S., Venn, B. J., & Slavin, J. L. (2018) · Nutrients · doi:10.3390/nu10101361 · Cited by 224
Umpierrez, G. E., Smiley, D., Hermayer, K., Khan, A., Olson, D. E., Newton, C., Jacobs, S., Rizzo, M., Peng, L., Reyes, D., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1988 · Cited by 222
Self-citationCardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222
Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221
Braffett, B. H., Gubitosi-Klug, R. A., Albers, J. W., Feldman, E. L., Martin, C. L., White, N. H., Orchard, T. J., Lopes-Virella, M., Lachin, J. M., Pop-Busui, R., et al. (2020) · Diabetes · doi:10.2337/db19-1046 · Cited by 221
Self-citationCarnethon, M. R., Prineas, R. J., Temprosa, M., Zhang, Z.-M., Uwaifo, G., Molitch, M. E., & for the Diabetes Prevention Program Research Group (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1729 · Cited by 220
Mathiesen, E. R., Hod, M., Ivanisevic, M., Duran Garcia, S., Brøndsted, L., Jovanovič, L., Damm, P., McCance, D. R., & on behalf of the Detemir in Pregnancy Study Group (2012) · Diabetes Care · doi:10.2337/dc11-2264 · Cited by 219
Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery
Barker, K. B., Palekar, N. A., Bowers, S. P., Goldberg, J. E., Pulcini, J. P., & Harrison, S. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00419.x · Cited by 218
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
The Look AHEAD Research Group (2014) · Diabetes Care · doi:10.2337/dc13-1928 · Cited by 217
Havers, F. P., Moro, P. L., Hunter, P., Hariri, S., & Bernstein, H. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6903a5 · Cited by 217
Brunelle, R. L., Llewelyn, J., Anderson, J. H., Gale, E. A. M., & Koivisto, V. A. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1726 · Cited by 216
Mendez, C. E., Mok, K.-T., Ata, A., Tanenberg, R. J., Calles-Escandón, J., & Umpierrez, G. E. (2013) · Diabetes Care · doi:10.2337/dc12-2430 · Cited by 216
Self-citationRajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0383 · Cited by 216
Thyroid Dysfunction in Patients With Type 1 Diabetes
Umpierrez, G. E., Latif, K. A., Murphy, M. B., Lambeth, H. C., Stentz, F., Bush, A., & Kitabchi, A. E. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1181 · Cited by 215
Self-citationGuerin, A., Nisenbaum, R., & Ray, J. G. (2007) · Diabetes Care · doi:10.2337/dc07-0278 · Cited by 215
Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215
Self-citationTay, J., Thompson, C. H., Luscombe‐Marsh, N. D., Wycherley, T. P., Noakes, M., Buckley, J. D., Wittert, G. A., Yancy, W. S., & Brinkworth, G. D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13164 · Cited by 215
Diabetes and obesity are the main metabolic drivers of peripheral neuropathy
Callaghan, B. C., Gao, L., Li, Y., Zhou, X., Reynolds, E. L., Banerjee, M., Pop‐Busui, R., Feldman, E. L., & Ji, L. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.531 · Cited by 215
Self-citationRamos, R., Comas-Cufí, M., Martí-Lluch, R., Balló, E., Ponjoan, A., Alves-Cabratosa, L., Blanch, J., Marrugat, J., Elosua, R., Grau, M., et al. (2018) · BMJ · doi:10.1136/bmj.k3359 · Cited by 215
The Diabetes Prevention Program Outcomes Study Research Group; prepared on behalf of the DPPOS Research Group, Orchard, T. J., Temprosa, M., Barrett‐Connor, E., Fowler, S. E., Goldberg, R. B., Mather, K. J., Marcovina, S. M., Montez, M., Ratner, R. E., et al. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03750.x · Cited by 214
Gaziano, J. M., Cincotta, A. H., O’Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 214
Exercise Intervention Studies in Patients with Peripheral Neuropathy: A Systematic Review
Streckmann, F., Zopf, E. M., Lehmann, H. C., May, K., Rizza, J., Zimmer, P., Gollhofer, A., Bloch, W., & Baumann, F. T. (2014) · Sports Medicine · doi:10.1007/s40279-014-0207-5 · Cited by 214
The Effect of Real-Time Continuous Glucose Monitoring in Pregnant Women With Diabetes
Secher, A. L., Ringholm, L., Andersen, H. U., Damm, P., & Mathiesen, E. R. (2013) · Diabetes Care · doi:10.2337/dc12-2360 · Cited by 214
Martínez-Cerón, E., Barquiel, B., Bezos, A.-M., Casitas, R., Galera, R., García-Benito, C., Hernanz, A., Alonso-Fernández, A., & Garcia-Rio, F. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-1942oc · Cited by 214
Efficacy of carbohydrate counting in type 1 diabetes: A systematic review and meta-analysis
Bell, K. J., Barclay, A. W., Petocz, P., Colagiuri, S., & Brand-Miller, J. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70144-x · Cited by 213
Treatment-induced diabetic neuropathy: A reversible painful autonomic neuropathy
Gibbons, C. H., & Freeman, R. (2010) · Annals of Neurology · doi:10.1002/ana.21952 · Cited by 213
Persson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13077 · Cited by 212
Galbete, C., Schwingshackl, L., Schwedhelm, C., Boeing, H., & Schulze, M. B. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0427-3 · Cited by 212
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
Papademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Kristensen, K., Ögge, L. E., Sengpiel, V., Kjölhede, K., Dotevall, A., Elfvin, A., Knop, F. K., Wiberg, N., Katsarou, A., Shaat, N., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4850-0 · Cited by 210
Pharmacokinetics of metformin during pregnancy
Eyal, S., Easterling, T. R., Carr, D., Umans, J. G., Miodovnik, M., Hankins, G. D. V., Clark, S. M., Risler, L., Wang, J., Kelly, E. J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031245 · Cited by 209
Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S., Kanwal, F., & Dulai, G. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01040.x · Cited by 208
Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review
Esposito, K., Maiorino, M. I., Ceriello, A., & Giugliano, D. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.04.019 · Cited by 208
Agarwal, P., Mukerji, G., Desveaux, L., Ivers, N. M., Bhattacharyya, O., Hensel, J. M., Shaw, J., Bouck, Z., Jamieson, T., Onabajo, N., et al. (2019) · JMIR mHealth and uHealth · doi:10.2196/10321 · Cited by 208
Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study
Hainsworth, D. P., Bebu, I., Aiello, L. P., Sivitz, W. I., Gubitosi‐Klug, R., Malone, J. I., White, N. H., Danis, R. P., Wallia, A., Gao, X., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2308 · Cited by 208
Self-citationDhatariya, K., & Care, T. J. B. D. S. F. I. (2022) · Diabetic Medicine · doi:10.1111/dme.14788 · Cited by 208
Sepah, S. C., Jiang, L., & Peters, A. L. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4052 · Cited by 206
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Kavanagh, B. P., & McCowen, K. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1001115 · Cited by 205
Nutrition Recommendations and Interventions for Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/dc06-9914 · Cited by 205
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 203
Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD
Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2729 · Cited by 203
Briggs Early, K., & Stanley, K. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2017.11.021 · Cited by 203
Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Obesity · doi:10.1002/oby.20585 · Cited by 202
Self-citationAdab, P., Pallan, M. J., Lancashire, E. R., Hemming, K., Frew, E., Barrett, T., Bhopal, R., Cade, J. E., Canaway, A., Clarke, J. L., et al. (2018) · BMJ · doi:10.1136/bmj.k211 · Cited by 202
Measures of Accuracy for Continuous Glucose Monitoring and Blood Glucose Monitoring Devices
Freckmann, G., Pleus, S., Grady, M., Setford, S., & Levy, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818812062 · Cited by 202
van Baar, A. C. G., Holleman, F., Crenier, L., Haidry, R., Magee, C., Hopkins, D., Rodriguez Grunert, L., Galvao Neto, M., Vignolo, P., Hayee, B., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318349 · Cited by 201
Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-analysis
Wiener, R. S., Wiener, D. C., & Larson, R. J. (2008) · JAMA · doi:10.1001/jama.300.8.933 · Cited by 200
Lee, S. W. H., Chan, C. K. Y., Chua, S. S., & Chaiyakunapruk, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-12987-z · Cited by 200
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Zhang, Q., Wu, Y., & Fei, X. (2016) · Medicina · doi:10.1016/j.medici.2015.11.008 · Cited by 197
Jackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.038 · Cited by 197
Condorelli, R. A., La Vignera, S., Mongioì, L. M., Alamo, A., & Calogero, A. E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00268 · Cited by 197
Billings, L. K., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H. W., Tentolouris, N., Grøn, R., Halladin, N., & Jódar, E. (2018) · Diabetes Care · doi:10.2337/dc17-1114 · Cited by 197
Crawford, F., Cezard, G. I., Chappell, F. M., Murray, G. D., Price, J. F., Sheikh, A., Simpson, C. R., Stansby, G. P., & Young, M. J. (2015) · Health Technology Assessment · doi:10.3310/hta19570 · Cited by 196
Brehm, B. J., Lattin, B. L., Summer, S. S., Boback, J. A., Gilchrist, G. M., Jandacek, R. J., & D’Alessio, D. A. (2009) · Diabetes Care · doi:10.2337/dc08-0687 · Cited by 196
Charleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02498 · Cited by 196
The importance of addressing depression and diabetes distress in adults with type 2 diabetes
Owens-Gary, M. D., Zhang, X., Jawanda, S., Bullard, K. M., Allweiss, P., & Smith, B. D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4705-2 · Cited by 194
Systematic review on urine albumin testing for early detection of diabetic complications
Newman, D., Mattock, M., Dawnay, A., Kerry, S., McGuire, A., Yaqoob, M., Hitman, G., & Hawke, C. (2005) · Health Technology Assessment · doi:10.3310/hta9300 · Cited by 192
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192
Glycemic Control in Non-Critically Ill Hospitalized Patients: A Systematic Review and Meta-Analysis
Murad, M. H., Coburn, J. A., Yglesias, F. C., Dzyubak, S., Hazem, A., Lane, M. A., Prokop, L. J., & Montori, V. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2100 · Cited by 192
Lachin, J. M., Bebu, I., Bergenstal, R. M., Pop‐Busui, R., Service, F. J., Zinman, B., & Nathan, D. M. (2017) · Diabetes Care · doi:10.2337/dc16-2426 · Cited by 192
Self-citationUtility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients With Hyperglycemia
Greci, L. S., Kailasam, M. T., Malkani, S., Katz, D. L., Hulinsky, I., Ahmadi, R., & Nawaz, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1064 · Cited by 191
Davis, C. R., Hodgson, J. M., Woodman, R., Bryan, J., Wilson, C., & Murphy, K. J. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.146803 · Cited by 191
De Nardi, A. T., Tolves, T., Lenzi, T. L., Signori, L. U., & Silva, A. M. V. D. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.017 · Cited by 191
Karter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. (2021) · JAMA · doi:10.1001/jama.2021.6530 · Cited by 191
UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
(1991) · PubMed · Cited by 191
Type ii diabetic subjects lose less weight than their overweight nondiabetic spouses
Wing, R. R., Marcus, M. D., Epstein, L. H., & Salata, R. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.563 · Cited by 190
Guldbrand, H., Dizdar, B., Bunjaku, B., Lindström, T., Bachrach-Lindström, M., Fredrikson, M., Östgren, C. J., & Nystrom, F. H. (2012) · Diabetologia · doi:10.1007/s00125-012-2567-4 · Cited by 189
Increased Mortality Risk in Women With Depression and Diabetes Mellitus
Pan, A., Lucas, M., Sun, Q., van Dam, R. M., Franco, O. H., Willett, W. C., Manson, J. E., Rexrode, K. M., Ascherio, A., & Hu, F. B. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.176 · Cited by 188
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Ohkuma, T., Peters, S. A. E., & Woodward, M. (2018) · Diabetologia · doi:10.1007/s00125-018-4664-5 · Cited by 188
Contribution of adipose tissue to development of cancer
Cozzo, A. J., Fuller, A. M., & Makowski, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170008 · Cited by 188
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga
Bakris, G. L., & Molitch, M. E. (2014) · Diabetes Care · doi:10.2337/dc13-1870 · Cited by 186
Current guidelines for obesity prevention in childhood and adolescence
Weihrauch-Blüher, S., Kromeyer-Hauschild, K., Graf, C., Widhalm, K., Korsten-Reck, U., Jödicke, B., Markert, J., Müller, M. J., Moss, A., Wabitsch, M., et al. (2018) · Obesity Facts · doi:10.1159/000486512 · Cited by 186
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Steck, A. K., Vehik, K., Bonifacio, E., Lernmark, A., Ziegler, A.-G., Hagopian, W. A., She, J., Simell, O., Akolkar, B., Krischer, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2426 · Cited by 185
Hansen, D., Dendale, P., Jonkers, R. A. M., Beelen, M., Manders, R. J. F., Corluy, L., Mullens, A., Berger, J., Meeusen, R., & van Loon, L. J. C. (2009) · Diabetologia · doi:10.1007/s00125-009-1354-3 · Cited by 185
Artificial Intelligence Screening for Diabetic Retinopathy: the Real-World Emerging Application
Bellemo, V., Lim, G., Rim, T. H., Tan, G. S. W., Cheung, C. Y.-L., Sadda, S. R., He, M., Tufail, A., Lee, M. L., Hsu, W., et al. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1189-3 · Cited by 184
Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31820c10eb · Cited by 183
Randomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183
Nutritionist Visits, Diabetes Classes, and Hospitalization Rates and Charges
Robbins, J. M., Thatcher, G. E., Webb, D. A., & Valdmanis, V. G. (2008) · Diabetes Care · doi:10.2337/dc07-1871 · Cited by 183
Interventions With Adherence-Promoting Components in Pediatric Type 1 Diabetes
Hood, K. K., Rohan, J. M., Peterson, C. M., & Drotar, D. (2010) · Diabetes Care · doi:10.2337/dc09-2268 · Cited by 183
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183
Female reproduction and type 1 diabetes: From mechanisms to clinical findings
Codner, E., Merino, P. M., & Tena-Sempere, M. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms024 · Cited by 182
Butler, C. C. (2006) · Family Practice · doi:10.1093/fampra/cml008 · Cited by 182
Simpson, D. M., Robinson‐Papp, J., Van, J. T., Stoker, M., Jacobs, H., Snijder, R. J., Schregardus, D. S., Long, S., Lambourg, B., & Katz, N. P. (2016) · Journal of Pain · doi:10.1016/j.jpain.2016.09.008 · Cited by 182
Azami, G., Soh, K. L., Sazlina, S. G., Salmiah, M. S., Aazami, S., Mozafari, M., & Taghinejad, H. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4930157 · Cited by 182
Papamichou, D., Panagiotakos, D. B., & Itsiopoulos, C. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.02.004 · Cited by 182
Xie, W., Dai, P., Qin, Y., Wu, M., Yang, B., & Yu, X. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-02892-1 · Cited by 182
Becker, B. N., Brazy, P. C., Becker, Y. T., Odorico, J. S., Pintar, T. J., Collins, B. H., Pirsch, J. D., LEVERSON, G. E., Heisey, D. M., & Sollinger, H. W. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00064.x · Cited by 181
Galindo, R. J., Migdal, A. L., Davis, G. M., Urrutia, M. A., Albury, B., Zambrano, C., Vellanki, P., Pasquel, F. J., Fayfman, M., Peng, L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2073 · Cited by 181
Self-citationLow-Intensity Exercise Reduces the Prevalence of Hyperglycemia in Type 2 Diabetes
MANDERS, R. J. F., VAN DIJK, J.-W. M., & VAN LOON, L. J. C. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181b3b16d · Cited by 180
Umpierrez, G. E., Hor, T., Smiley, D. D., Temponi, Á., Umpierrez, D., Cerón, M., Munoz, C., Newton, C. A., Peng, L., & Baldwin, D. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1441 · Cited by 180
Self-citationLiu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180
on behalf of the Diabetes and Cancer Research Consortium, Carstensen, B., Read, S. H., Friis, S., Sund, R., Keskimäki, I., Svensson, A.-M., Ljung, R., Wild, S. H., Kerssens, J. J., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3884-9 · Cited by 180
Obeid, A., Su, D., Patel, S. N., Uhr, J. H., Borkar, D., Gao, X., Fineman, M. S., Regillo, C. D., Maguire, J. I., Garg, S. J., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.027 · Cited by 180
Self-citationCourcoulas, A. P., Gallagher, J. W., Neiberg, R. H., Eagleton, E. B., DeLany, J. P., Lang, W., Punchai, S., Gourash, W., & Jakicic, J. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa006 · Cited by 180
Guraya, S. Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.6026 · Cited by 179
Becerra-Tomás, N., Díaz-López, A., Rosique-Esteban, N., Ros, E., Buil-Cosiales, P., Corella, D., Estruch, R., Fitó, M., Serra-Majem, L., Arós, F., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.03.015 · Cited by 179
Verjans-Janssen, S. R. B., van de Kolk, I., Van Kann, D. H. H., Kremers, S. P. J., & Gerards, S. M. P. L. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204560 · Cited by 179
Greenway, F. L., Aronne, L. J., Raben, A., Astrup, A., Apovian, C. M., Hill, J. O., Kaplan, L. M., Fujioka, K., Matejkova, E., Svacina, S., et al. (2019) · Obesity · doi:10.1002/oby.22347 · Cited by 179
Li, J. Q., Welchowski, T., Schmid, M., Letow, J., Wolpers, C., Pascual-Camps, I., Holz, F. G., & Finger, R. P. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-019-00560-z · Cited by 179
The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0024 · Cited by 178
Mansberger, S. L., Sheppler, C., Barker, G., Gardiner, S. K., Demirel, S., Wooten, K., & Becker, T. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.1 · Cited by 177
Corona, G., Rastrelli, G., & Maggi, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.002 · Cited by 177
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
van Zuuren, E. J., Fedorowicz, Z., Kuijpers, T., & Pijl, H. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy096 · Cited by 177
Naik, A. D., Palmer, N., Petersen, N. J., Street, R. L., Rao, R., Suarez-Almazor, M., & Haidet, P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.70 · Cited by 176
Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities
Boucai, L., Southern, W. N., & Zonszein, J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.07.011 · Cited by 175
Vaccines for preventing herpes zoster in older adults
Gagliardi, A. M., Andriolo, B. N., Torloni, M. R., & Soares, B. G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008858.pub3 · Cited by 175
Flagged first, then by citations
97 of the 1959 references couldn’t be matched to a known paper.
Research works printed but not linked: 9
- Gillett, 2009, International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: Diabetes care, Clin Biochem Rev, 30, 197
- 1991, VIII. Study design, progress and performance, Diabetologia, 34, 877
- Nußbaumer, 2016, Ezetimibe-statin combination therapy, Dtsch arztebl int, 113, 445
- Whelton, 2018, Hypertens (Dallas. TX, 71, e13
- 2012, KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, 279
- Miller, 2015, Erratum. J Fam Pract, 64, 452
- Mechanick, 2019, Endocr Pract, 25, 1346
- 2019, Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study, Diabetes Care, 42, 601, 10.2337/dc18-1970 · DOI · Paper page
- American Diabetes Association. Medical management of pregnancy complicated by diabetes fourth edition. Jovanovic L, ed. Alexandria, VA: American Diabetes Association, 2009.
Cited by
Sorted by citations
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Self-citationDisorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Baricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
Honarmand, K., Sirimaturos, M., Hirshberg, E. L., Bircher, N. G., Agus, M. S. D., Carpenter, D. L., Downs, C. R., Farrington, E. A., Freire, A. X., Grow, A., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006174 · Cited by 177
Self-citationNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Self-citation
Metadata
- Authors
- Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., Gardner, T. W., Garg, R., Garvey, W. T., Hirsch, I. B., Hurley, D. L., Izuora, K., Kosiborod, M., Olson, D., Patel, S. B., Pop-Busui, R., Sadhu, A. R., Samson, S. L., Stec, C., Tamborlane, W. V., Tuttle, K. R., Twining, C., Vella, A., Vellanki, P., & Weber, S. L.
- Affiliations
- Ochsner Health System (US)
- Emory University (US)
- Central Michigan University (US)
- Washington University in St. Louis (US)
- University at Buffalo, State University of New York (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio (US)
- Scripps Whittier Diabetes Institute (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- Mayo Clinic (US)
- University of Nevada, Las Vegas (US)
- Saint Luke's Hospital (US)
- Colorado Health Foundation (US)
- University of Cincinnati Medical Center (US)
- Houston Methodist (US)
- Mayo Clinic in Florida (US)
- American Association of Clinical Endocrinologists (US)
- Yale University (US)
- Maine Medical Center (US)
- Prisma Health (US)
- ORCID
- Blonde, Lawrence
- Umpierrez, Guillermo E.
- McGill, Janet B.
- Berga, Sarah L.
- Bush, Michael
- Chandrasekaran, Suchitra
- DeFronzo, Ralph A.
- Einhorn, Daniel
- Galindo, Rodolfo J.
- Gardner, Thomas W.
- Garg, Rajesh
- Garvey, W. Timothy
- Hirsch, Irl B.
- Hurley, Daniel L.
- Izuora, Kenneth
- Kosiborod, Mikhail
- Patel, Shailendra B.
- Sadhu, Archana R.
- Samson, Susan L.
- Tamborlane, William V.
- Tuttle, Katherine R.
- Vella, Adrian
- Vellanki, Priyathama
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 923-1049
- ISSN
- 1530-891X (ISSN-L)
- PMC
- PMC10200071
- OpenAlex
- W4291397630
- Cited by
- 507
- References
- 1,959
- Citations by year
- 2026: 95 · 2025: 119 · 2024: 150 · 2023: 134 · 2022: 9
- FWCI
- 76.49
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-01)
- Open access
- bronze
- doi.org
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (K23DK123384, P30DK111024)
- National Institute of Diabetes and Digestive and Kidney Diseases
- BP
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- diabetes mellitus, comprehensive diabetes care, glycemic targets, blood glucose monitoring, diabetes complications, obesity, bariatric surgery, hypertension, dyslipidemia, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, cardiovascular disease, prediabetes, type 2 diabetes, type 1 diabetes, insulin therapy, hypoglycemia, diabetes in pregnancy, diabetes education, infertility, dietary supplements, social determinants of health, virtual care, cancer risk, pediatric diabetes care, depression, sleep medicine, team-based care
- MeSH terms
- Child, Diabetes Mellitus, Type 2, Endocrinology, Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, United States, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v1).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
